Cartography Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cartography Biosciences, Inc. - overview
Established
2020
Location
San Carlos, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2020 by its CEO Kevin Parker, and co-founders Howard Chang, and Ansu Satpathy, Cartography Biosciences, Inc. operates as a therapeutics company that provides medicine for immuno-oncology and cancers. In May 2026, Cartography Biosciences, Inc. raised venture funding from Samsung Venture Investment.
Cartography Biosciences, Inc. offers a platform that integrates cutting-edge computational and experimental techniques, including single-cell genomics and proteomics to create immunotherapies by identifying the targets that maximize efficacy, and analyze cancers while minimizing potentially toxic side effects.
Current Investors
Alexandria Venture Investments, ARTIS Ventures, Andreessen Horowitz
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.cartography.bio
Company Stage
Series B
Total Amount Raised
Subscriber access only
Cartography Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.